Anika Therapeutics ANIK
Jump To Section
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Business overview of Anika Therapeutics (ANIK)
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States.
Key Insights
Critical company metrics and information
Latest Closing Price
$16.62Market Cap
$243.41 MillionPrice-Earnings Ratio
-2.50Total Outstanding Shares
14.65 Million SharesTotal Employees
357Dividend
No dividendIPO Date
May 3, 1993SIC Description
Surgical & Medical Instruments & ApparatusPrimary Exchange
NASDAQType
Common StockHeadquarters
32 wiggins avenue, Bedford, MA, 01730Homepage
https://www.anika.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow | $-8.44 Million |
Net Cash Flow From Investing Activities, Continuing | $-8.87 Million |
Net Cash Flow From Investing Activities | $-8.87 Million |
Net Cash Flow From Operating Activities, Continuing | $7.46 Million |
Net Cash Flow From Financing Activities, Continuing | $-7.03 Million |
Net Cash Flow From Financing Activities | $-7.03 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Cost Of Revenue | $84.41 Million |
Basic Average Shares | $14.77 Million |
Revenues | $164.17 Million |
Operating Income/Loss | $-96.70 Million |
Net Income/Loss Attributable To Parent | $-97.52 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
Comprehensive Income
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
Comprehensive Income/Loss Attributable To Parent | $-96.66 Million |
Comprehensive Income/Loss | $-96.66 Million |
Other Comprehensive Income/Loss | $20.53 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Liabilities | $51.54 Million |
Current Assets | $136.11 Million |
Accounts Payable | $6.80 Million |
Other Current Assets | $96.48 Million |
Equity | $179.86 Million |
Equity Attributable To Noncontrolling Interest | $0 |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Recent Headlines From The Web
Latest news, press releases, and media coverage about ANIK from trusted financial sources
Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2025 Financhle. All Rights Reserved.